“Amniotic Membrane Market Report is set to have rapid growth due the rising awareness and the presence of technologically advanced countries in terms of healthcare and medical research at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Amniotic Membrane Market Forecast 2019-2029: By End Use (ASC, Hospital), By Enzyme (Dehydrated, Cryopreserved), By Application (Ophthalmology, Surgical Wounds), Region and Segment Forecasts

The global Amniotic Membrane market is poised for rapid growth between 2019 and 2029. The growing awareness in the recent past has led to an increase in the number of transplants which has led to a growing demand for these tissue-based products. It has also led to an increase in the number of donations, thus fueling market growth.

The main factors driving the growth of the amniotic membrane market is the increase in the geriatric population combined with the increase in transplantation based on the amniotic membrane at the global level. However, the lack of qualified professionals and the high cost of surgical interventions involving the amniotic membrane slow the growth of the global amniotic membrane market. Furthermore, increasing awareness of the potential benefits of the amniotic membrane between patients and healthcare professionals offers profitable opportunities that promote the market.

Leading companies featured in the report include Alliqua BioMedical, Inc.; Amnio Technology, LLC; Applied Biologics LLC; Human Regenerative Technologies, LLC; DermaSciences; Katena Products, Inc.; MiMedx Group, Inc.; Skye Biologics, Inc.; Amniox Medical, Inc.; and Organogensis, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever